AI in Bioinformatics Market Report 2026

The ai in bioinformatics market size has grown exponentially in recent years. It will grow from $6.14 billion in 2025 to $8.81 billion in 2026 at a compound annual growth rate (CAGR) of 43.6%. The growth in the historic period can be attributed to growing volume of genomic data, rising adoption of next-generation sequencing, increasing bioinformatics research funding, early integration of ML in life sciences, expansion of public biological databases.

The ai in bioinformatics market size is expected to see exponential growth in the next few years. It will grow to $37.63 billion in 2030 at a compound annual growth rate (CAGR) of 43.7%. The growth in the forecast period can be attributed to increasing demand for precision medicine, rising use of AI in clinical decision support, growing pharmaceutical R&D investments, advancements in deep learning architectures, increasing need for faster drug development cycles. Major trends in the forecast period include ai-driven genomic data interpretation, automated drug discovery and target identification, integration of multi-omics data platforms, cloud-based bioinformatics workflows, advanced predictive modeling for protein structures.

The growing number of clinical trials is expected to drive the expansion of AI in the bioinformatics market in the coming years. Clinical trials are a systematic and carefully structured process of conducting medical research with human participants to evaluate the safety, efficacy, and effectiveness of new treatments, drugs, medical devices, or therapeutic approaches. AI in bioinformatics is applied in clinical trials to analyze patient data from electronic health records and other sources, helping identify potential participants who meet specific criteria, thereby improving recruitment efficiency and targeting. For example, in May 2023, according to Xtalks, a Canada-based provider of life science webinars and virtual events, a total of 452,604 clinical studies were registered on ClinicalTrials.gov as of May 17, 2023, with 64,838 studies actively recruiting participants. Therefore, the increasing volume of clinical trials is supporting the growth of AI in the bioinformatics market.

Major companies in the AI in bioinformatics market are advancing technological innovations on the Bionl.AI platform to enhance their market profitability. Bionl.AI provides a comprehensive workspace for exploration, analysis, and visualization, reducing the time required to complete complex tasks from days to minutes. For instance, in October 2023, Bionl Inc., a US-based biomedical and bioinformatics research platform company, launched Bionl.AI, an innovative platform designed to transform biomedical and bioinformatics research by offering a no-code solution for researchers, students, and professionals to explore biomedicine using natural language queries. The platform utilizes advanced GenAI models to deliver instant insights and make complex analyses more accessible and engaging.

In August 2024, Seqera, a Spain-based provider of scientific data analysis solutions for life sciences and creator of Nextflow, acquired Tinybio for an undisclosed amount. This acquisition supports Seqera’s strategy to strengthen its capabilities in AI-powered bioinformatics tools and enhance its online platform for empowering scientists. Tinybio is a US-based tech-bio startup specializing in bioinformatics solutions.

Major companies operating in the ai in bioinformatics market are Dassault Systèmes SE, QIAGEN N.V., SomaLogic Operating Co. Inc., Seven Bridges Genomics Inc., Genialis Inc., SOPHiA GENETICS SA, DNAnexus Inc., Insilico Medicine Inc., Deep Genomics Inc., Biomax Informatics Inc., Ardigen SA, Strand Life Sciences Pvt. Ltd., Genomenon Inc., Fios Genomics Limited, BlueBee Holding BV, JADBio, Elucidata Corporation, Gnosis DA, DNASTAR Inc., iNDX.Ai, Paige AI Inc.

North America was the largest region in the AI in bioinformatics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ai in bioinformatics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ai in bioinformatics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the AI in bioinformatics market by increasing costs associated with high-performance computing hardware, data storage infrastructure, and specialized software components used in biological data analysis. These impacts are most visible across software and services offerings supporting genomics, proteomics, and drug discovery applications, with North America and Asia-Pacific regions experiencing supply chain and pricing pressures due to their reliance on global technology imports. At the same time, tariffs are encouraging local software development, regional cloud infrastructure expansion, and increased investment in domestic AI platforms, creating long-term opportunities for localized innovation and reduced dependency on imported technologies.

The ai in bioinformatics market research report is one of a series of new reports that provides ai in bioinformatics market statistics, including ai in bioinformatics industry global market size, regional shares, competitors with a ai in bioinformatics market share, detailed ai in bioinformatics market segments, market trends and opportunities, and any further data you may need to thrive in the ai in bioinformatics industry. This ai in bioinformatics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

AI in bioinformatics refers to the use of artificial intelligence (AI) methods and algorithms to analyze and interpret biological data. Bioinformatics focuses on the organization and analysis of large, complex biological datasets, including genomic sequences, protein structures, and other types of biological information.

The main categories of AI in bioinformatics include machine learning, deep learning, and others. Machine learning (ML) is a branch of AI that involves creating algorithms and statistical models that allow computer systems to perform tasks without being explicitly programmed. It provides tools and software and is applied in areas such as genomics, chemoinformatics and drug design, proteomics, DNA sequencing, systems biology, transcriptomics, text mining, microarrays, metabolomics, and other related applications.

The AI in the bioinformatics market includes revenues earned by entities by providing services such as data analysis and interpretation, biomarker discovery services, clinical decision support, diagnostic imaging software, and biomarker discovery tools. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in the bioinformatics market also includes sales of high-performance computing (HPC) clusters, graphics processing units (GPUs), and field-programmable gate arrays (FPGAs). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.